financetom
Business
financetom
/
Business
/
Nike to post worst revenue fall in 5 years on stagnant demand
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Nike to post worst revenue fall in 5 years on stagnant demand
Mar 19, 2025 2:04 PM

(Reuters) - Nike ( NKE ) is expected to post its steepest revenue decline in nearly five years in its quarterly results on Thursday, as its new products failed to open the wallets of Americans reluctant to snap up non-essential items like sporting goods and clothing.

Downloads of Nike ( NKE ) mobile apps for the quarter were down 35% from a year earlier, according to market intelligence firm Sensor Tower. Foot traffic at Nike ( NKE ) stores was down 11%, according to data compiled by Raymond James.

Foot Locker ( FL ), a major Nike ( NKE ) retailer, disclosed in its earnings March 5 that promotional pressures would hurt its profit margins in the year ahead. This signaled the impact of discounts imposed by Nike ( NKE ) to clear out unsold inventory.

Nike ( NKE ) products comprise more than 60% of Foot Locker ( FL ) merchandise.

Those recent indicators illustrate the long road ahead for Nike ( NKE ) and its new CEO Elliott Hill, who assumed the top job in October. Nike ( NKE ) shares have slid 19% since September 20, following Hill's appointment. Rival Adidas, meanwhile, has seen its stock tick up slightly over the same period.

Under Hill, Nike ( NKE ) began an ambitious turnaround, though Morningstar analyst David Swartz said one or two snazzy new styles will not be enough to get the sportswear giant back on track for sales growth.

"It needs to create a whole new franchise, like a family of products that add billions in sales," Swartz said. "That takes years."

Nike ( NKE ) is expected to post a revenue decline of 11.5% to $11.01 billion in the third quarter, according to data compiled by LSEG. It would be the steepest fall since the 38% decline Nike ( NKE ) reported in fourth quarter of fiscal 2020 during the pandemic.

Its earnings per share is expected to come in at 29 cents, down sharply from 77 cents a year earlier. Investors told Reuters they were keen for details on Nike's ( NKE ) efforts to rebuild relationships with retailers and clear out unsold inventory.

"It continues to be a 'show-me' story," said Jay Woods, chief global strategist at investment banking firm Freedom Capital Markets. "The question is, do investors have the patience?"

Nike's ( NKE ) inventories were $8 billion in the quarter ended November 30, according to the company.

Some of Hill's moves so far - including the launch of running shoes Pegasus Premium and Vomero 18 in January and February; a new partnership with womenswear company Skims; and its first Super Bowl ad in 27 years - drew praise from John Nagle, chief investment officer of Kavar Capital Partners LLC, which holds Nike ( NKE ) shares.

The planned women's line with Kim Kardashian-owned Skims "would be pretty good for the business," said Nagle, "if they can even just step into that market and be a significant player alongside the Lululemons and Biores."

The Super Bowl commercial, conceived with ad agency Widen + Kennedy, was intended to reach women shoppers, and to demonstrate Nike's ( NKE ) marketing prowess and regain its pop culture relevance.

The spot featured top female athletes like Caitlin Clark, the basketball superstar who has been central to the newfound surge in popularity of the Women's National Basketball Association.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Genmab Gets FDA Approval for Follicular Lymphoma Treatment
Genmab Gets FDA Approval for Follicular Lymphoma Treatment
Jun 27, 2024
05:02 AM EDT, 06/27/2024 (MT Newswires) -- Genmab A/S ( GMAB ) said late Wednesday that the US Food and Drug Administration approved Epkinly, or epcoritamab-bysp, for the treatment of adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. This indication has been given the green signal under the FDA's accelerated approval program based...
Regeneron, Sanofi Eosinophilic Esophagitis Treatment Showed Improvements for Children in Phase 3 Study
Regeneron, Sanofi Eosinophilic Esophagitis Treatment Showed Improvements for Children in Phase 3 Study
Jun 27, 2024
04:52 AM EDT, 06/27/2024 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) and Sanofi ( SNY ) said Wednesday that a phase 3 trial showed that a greater proportion of children with eosinophilic esophagitis receiving their drug Dupixent showed significant improvements in disease measures compared with those that received a placebo. The results of the trial were published in the...
Boeing to brief European regulators on new production plans after 737 MAX panel blowout
Boeing to brief European regulators on new production plans after 737 MAX panel blowout
Jun 27, 2024
SEATTLE, June 27 (Reuters) - Boeing ( BA ) is planning a briefing for high-level European regulatory officials about changes to the way it makes planes, a senior company executive said, after a January mid-air panel blowout sparked a safety crisis. Boeing ( BA ) has been under pressure over factory controls since Jan. 5, when a door plug tore...
Drugmaker Servier loses EU court fight over pay-for-delay deals
Drugmaker Servier loses EU court fight over pay-for-delay deals
Jun 27, 2024
BRUSSELS (Reuters) -French drugmaker Servier on Thursday lost its court battle against a European Union fine for deals with rivals to delay sales of generic copies of its top-selling blood pressure medicine perindopril. The European Commission fined Servier 331 million euros ($354 million) in 2014 - and also fined generic drugmakers Teva, Unichem and its subsidiary Niche, Matrix which is...
Copyright 2023-2026 - www.financetom.com All Rights Reserved